MARKET

PPCB

PPCB

Propanc Bio
OTCPK
5.68
NaN%
Opening 09:30 03/21 EDT
OPEN
--
PREV CLOSE
5.68
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
270.00
52 WEEK LOW
2.070
MARKET CAP
63.49K
P/E (TTM)
-0.0095
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PPCB last week (0310-0314)?
Weekly Report · 4d ago
Weekly Report: what happened at PPCB last week (0303-0307)?
Weekly Report · 03/10 09:35
Weekly Report: what happened at PPCB last week (0224-0228)?
Weekly Report · 03/03 09:35
Weekly Report: what happened at PPCBD last week (0217-0221)?
Weekly Report · 02/24 09:35
Weekly Report: what happened at PPCBD last week (0210-0214)?
Weekly Report · 02/17 09:34
Based on the provided financial report articles, I generated the title for the article: **"PPCB's Financial Report for Q2 2025: A Comprehensive Review of the Company's Financial Performance"** Please note that the title may not be exact, as the provided text does not contain a clear title. However, based on the content, I inferred the title to be a financial report for PPCB (Publicly Traded Company B) for the second quarter of 2025.
Press release · 02/15 06:39
Weekly Report: what happened at PPCBD last week (0203-0207)?
Weekly Report · 02/10 09:33
Weekly Report: what happened at PPCBD last week (0127-0131)?
Weekly Report · 02/03 09:34
More
About PPCB
Propanc Biopharma, Inc. is an Australia-based clinical biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.

Webull offers Propanc Biopharma Inc stock information, including OTCPK: PPCB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PPCB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PPCB stock methods without spending real money on the virtual paper trading platform.